Table 2.
Summary of OCAC samples used for the replication study
| Controls |
Cases |
||||
|---|---|---|---|---|---|
| OCAC site |
Study Name | Controls (non- Hispanic White) |
Cases (non- Hispanic White) |
Invasive case (non- Hispanic White)a |
Invasive serous cases (non- Hispanic White)b |
| AUSc | Australia Ovarian Cancer Study/Australian Cancer Study |
576 (524) | 1276 (1207) | 921 | 502 |
| BEL | Belgium Ovarian Cancer Study | 428 (428) | 257 (253) | 197 | 128 |
| GER | German Ovarian Cancer Study | 420 (420) | 252 (251) | 223 | 105 |
| HJO/HMO | Hannover-Jena and Hannover- Minsk Ovarian Cancer Study |
913 (903) | 467 (463) | 246 | 70 |
| HAW | Hawaii Ovarian Cancer Study | 625 (166) | 417 (102) | 81 | 43 |
| HOCS | Helsinki Ovarian Cancer Study | 456 (456) | 262 (262) | 261 | 130 |
| NTH | Nijmegen Polygene Study & Nijmegen Biomedical Study |
599 (598) | 305 (300) | 297 | 101 |
| MAL | Danish Malignant Ovarian Tumour Study |
1075 (1075) |
263 (263) | 263 | 162 |
| NJO | New Jersey Ovarian Cancer Study |
189 (173) | 200 (177) | 176 | 105 |
| OVA | Ovarian Cancer in Alberta and British Columbia Study |
530 (460) | 834 (706) | 538 | 291 |
| SEA | UK SEARCH Ovarian Cancer Study |
1231 (1227) |
1172 (1160) | 972 | 377 |
| UKO | UK Ovarian Cancer Population Study |
542 (536) | 490 (476) | 476 | 231 |
| Total | 7584 (6966) |
6195 (5620) | 4651 | 2245 | |
a
Cases eligible for secondary analysis in the replication.
b
Cases eligible for primary analysis in the replication.
c
AOCS cases and controls included in the pools using in stage 1 were excluded from analysis in the replication study.